Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study

BACKGROUND: On Dec 8, 2020, deployment of the first SARS-CoV-2 vaccination authorised for UK use (BNT162b2 mRNA vaccine) began, followed by an adenoviral vector vaccine ChAdOx1 nCoV-19 on Jan 4, 2021. Care home residents and staff, frontline health-care workers, and adults aged 80 years and older we...

Descripción completa

Detalles Bibliográficos
Autores principales: Hyams, Catherine, Marlow, Robin, Maseko, Zandile, King, Jade, Ward, Lana, Fox, Kazminder, Heath, Robyn, Tuner, Anabella, Friedrich, Zsolt, Morrison, Leigh, Ruffino, Gabriella, Antico, Rupert, Adegbite, David, Szasz-Benczur, Zsuzsa, Garcia Gonzalez, Maria, Oliver, Jennifer, Danon, Leon, Finn, Adam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8221734/
https://www.ncbi.nlm.nih.gov/pubmed/34174190
http://dx.doi.org/10.1016/S1473-3099(21)00330-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8221734/
https://www.ncbi.nlm.nih.gov/pubmed/34174190
http://dx.doi.org/10.1016/S1473-3099(21)00330-3

Ejemplares similares